Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers. | Int J Mol Sci | 2023 | 37373521 | PubTator, text mining | PubMed |
| Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review. | Int J Mol Sci | 2023 | 37373354 | PubTator, text mining | PubMed |
| Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials. | Int J Mol Sci | 2023 | 37373078 | PubTator, text mining | PubMed |
| Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group. | Ann Hematol | 2023 | 37358640 | PubTator, text mining | PubMed |
| Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients. | Br J Haematol | 2023 | 37357817 | PubTator, text mining | PubMed |
| [Standardize and enhance the diagnosis and treatment capabilities of chronic lymphoblastic leukemia in China]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37356993 | PubTator, text mining | PubMed |
| Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: Common Inflammatory Pathways of Two Distinct Diseases. | Rheum Dis Clin North Am | 2023 | 37331738 | PubTator, text mining | PubMed |
| Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis. | Sci Rep | 2023 | 37328530 | PubTator, text mining | PubMed |
Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study. | Microorganisms | 2023 | 37317279 | PubTator, text mining | PubMed |
| Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. | Blood Adv | 2023 | 37315225 | PubTator, text mining | PubMed |
| B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. | Clin Cancer Res | 2023 | 37314786 | PubTator, text mining | PubMed |
| Robust CRISPR-Cas9 Genetic Editing of Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells. | Hemasphere | 2023 | 37304935 | PubTator, text mining | PubMed |
| Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study. | Cancers (Basel) | 2023 | 37296954 | PubTator, text mining | PubMed |
| A CAPTIVATEing Analysis for Higher-Risk CLL. | Clin Cancer Res | 2023 | 37289004 | PubTator, text mining | PubMed |
| Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). | Curr Hematol Malig Rep | 2023 | 37278884 | PubTator, text mining | PubMed |
| Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non-specific hypersensitivity reactions. | Skin Health Dis | 2023 | 37275409 | PubTator, text mining | PubMed |
| Telomere biology: from disorders to hematological diseases. | Front Oncol | 2023 | 37274248 | PubTator, text mining | PubMed |
| Editorial: The notch signaling pathway in lymphoid malignancies. | Front Oncol | 2023 | 37260980 | PubTator, text mining | PubMed |
| Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics. | JCI Insight | 2023 | 37252802 | PubTator, text mining | PubMed |
| Genomic Stratification of Hematological Malignancies. | Hemasphere | 2023 | 37251914 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=17